Travoprost
As of the edition of 20 October 2026, Travoprost is a small molecule: marketed, first approved in 2001 (US); acts on PTGFR; no US protection of its own is listed.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2017
- Kind
- Small molecule
- Brand name
- Travatan
- First approved
- 16 March 2001 (US)
- Approvals on record
- 14 in 7 regions
- Holder of the most recent approval
- Glaukos; 8 holders in all
- Registered trials
- 84, 10 stopped early
- Disease areas
- Eye; Heart and blood vessels; Inherited and neonatal; Skin and connective tissue
US protection
No US protection of its own is listed.
The FDA registers list no drug-substance patent or exclusivity of its own that counts for this drug.
Glaukos holds a later exclusivity on its own new formulation or combination product, ending 2031; it does not protect the original drug.
This is the US only.
Companies that need a new molecule because of this drug
2 companies on route B because of this drug.
Companies on route B for this drug
In the product2 companies are on route B because of Travoprost.
See the 2 companies on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| PTGFR | Prostaglandin F2-alpha receptor | P43088 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 15 | 11 | 0 | 3 |
| Phase 1 | 2 | 2 | 0 | 0 |
| Phase 2 | 9 | 8 | 0 | 0 |
| Phase 3 | 21 | 17 | 0 | 3 |
| Phase 4 | 37 | 30 | 2 | 4 |
| All trials | 84 |